<DOC>
	<DOCNO>NCT01711658</DOCNO>
	<brief_summary>PURPOSE : This trial study well lapatinib add effectiveness radiation therapy plus cisplatin patient head neck cancer relate HPV virus .</brief_summary>
	<brief_title>TRYHARD : Radiation Therapy Plus Cisplatin With Without Lapatinib Treating Patients With Head Neck Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion : Patients must histologically cytologically confirm diagnosis ( primary lesion and/or lymph node ) Squamous Cell Cancer oropharynx , hypopharynx larynx ( For patient oropharynx primary , tumor must negative p16 immunohistochemistry ) . Patients selected Stage III IV disease ( T2 N23 M0 , T34 N M0 , T1 N2b , N2c N3p16 negative oropharynx cancer T12 N hypopharynx cancer ) include distant metastasis . History/Physical examination Radiation Oncologist Medical oncologist prior enter study . Examination ENT Head &amp; Neck Surgeon include laryngopharyngoscopy prior enter study . Patients must chest CT scan , PET/CT scan rule metastatic disease Patients must contrast enhanced CT scan MRI PET/CT scan tumor site neck node prior enter study . Patients must EKG ECHO MUGA scan prior enter study . Patients must Zubrod Performance Status 01 . Patients must ≥ 18 year age . Patients must normal organ marrow function define : Absolute neutrophil count ( ANC ) ≥ 1,500 cells/mm3 Platelets ≥ 100,000 cells/mm3 Hemoglobin ≥ 8.0 g/dl Serum creatinine &lt; 1.5 mg/dl creatinine clearance ( CC ) ≥ 50 ml/min Total bilirubin &lt; 2 x institutional upper limit normal AST ALT ≤ 3 x institutional upper limit normal Patient must magnesium , calcium , glucose , potassium sodium level within normal limit Women childbearing potential must negative pregnancy test prior registration . Patients reproductive potential must practice effective contraception study least 60 calendar day follow treatment . All patient must sign informed consent prior enrollment . Patients must comply treatment plan followup schedule . Exclusion criterion : Patients simultaneous primary bilateral tumor . Patients gross total excision primary tumor . Patients initial surgical treatment , radical modify neck dissection . Patients receive prior systemic chemotherapy study cancer . Patients receive prior radiotherapy region study cancer would result overlap radiation therapy field . Patients primary tumor oral cavity , nasopharynx , sinus salivary gland . Prior allergic reaction study drug . Patients prior therapy specifically directly target EGFR/HER2 pathway . Patients current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , stable chronic liver disease per investigator assessment ) ; Pregnant woman sexually active patient willing able use medically acceptable form contraceptive method treatment . Patients severe , active comorbidity , define follow : Uncontrolled cardiac disease , uncontrolled hypertension , unstable angina , and/or congestive heart failure require hospitalization within last 6 month Transmural myocardial infarction within last 6 month Left ventricular ejection fraction &lt; 45 % Acute bacterial fungal infection require intravenous antibiotic time registration Chronic Obstructive Pulmonary Disease exacerbation respiratory illness require hospitalization preclude study therapy within 30 calendar day prior registration Hepatic insufficiency result clinical jaundice and/or Coagulation defect Acquired Immune Deficiency Syndrome ( AIDS ) base upon current CDC definition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>